New Technology Detects Risks of Drugs to Heart Sooner
Software for Heart
A new technology to enable pharmaceutical companies to determine more effectively, and earlier on in clinical trials, whether an experimental drug is toxic to the heart has taken an important step toward the marketplace.
The University of Rochester Medical Center (URMC) and iCardiac Technologies, Inc. have signed an exclusive agreement to commercialize software developed by biomedical engineer Jean-Philippe Couderc, Ph.D., that provides a more accurate and reliable method to analyze data from electrocardiograms (ECG) and other types of heart monitors to determine whether a drug is toxic to the heart.
The technology consists of software known as COMPAS